BioLineRx Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx or view top-rated stocks.

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioLineRx saw a drop in short interest in March. As of March 15th, there was short interest totaling 444,600 shares, a drop of 34.2% from the February 28th total of 675,400 shares. Based on an average daily volume of 2,010,000 shares, the short-interest ratio is presently 0.2 days.
View BioLineRx's Short Interest.

BioLineRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for BioLineRx.

BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings results on Tuesday, February, 23rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.36.
View BioLineRx's earnings history.

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLRX stock has increased by 72.5% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 12 month price targets for BioLineRx's shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate BioLineRx's stock price to reach $19.00 in the next year. This suggests a possible upside of 588.4% from the stock's current price.
View analysts' price targets for BioLineRx or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioLineRx include Flexion Therapeutics (FLXN), 89bio (ETNB), Forte Biosciences (FBRX), Fortress Biotech (FBIO), Akebia Therapeutics (AKBA), Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Geron (GERN), Catalyst Pharmaceuticals (CPRX), Foghorn Therapeutics (FHTX), Inozyme Pharma (INZY), Summit Therapeutics (SMMT), CytomX Therapeutics (CTMX), Molecular Templates (MTEM) and Kala Pharmaceuticals (KALA).
View all of BLRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLRX stock can currently be purchased for approximately $2.76.

BioLineRx has a market capitalization of $117.61 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

BioLineRx employs 38 workers across the globe.

The official website for BioLineRx is www.biolinerx.com.

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]